biblioteca virtual en salud

Búsqueda | Gripe por A(H1N1)

  • BIREME | OPAS | OMS logo

Historico de búsqueda  ()

Su selección  ()

 0 documento(s) seleccionado(s).

Enviar por email

Ud. tiene 0 documento(s) seleccionado(s).

Ningún documento seleccionado

Resultados  1-12 de 282

Interplay between influenza A virus and host factors: targets for antiviral intervention.

Autor(es): Tripathi S; Batra J; Lal SK
Fuente: Arch Virol;160(8): 1877-91, 2015 Aug.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 26016443
Resumen: Influenza A viruses (IAVs) pose a major public health threat worldwide. Recent experience with the 2013 H7N9 outbreak in China and the 2009 "swine flu" pandemic have shown that antiviral vaccines and drugs fall short of controlling the spread of disease in a timely and effective manner. Major problems include rapid emergence of drug-resistant influenza virus strains and the slow process of vaccine production. With the threat of a highly pathogenic H5N1 bird-flu pandemic looming large, it is (mas)

Mouse lung slices: An ex vivo model for the evaluation of antiviral and anti-inflammatory agents against influenza viruses.

Autor(es): Liu R; An L; Liu G; Li X; Tang W; Chen X
Fuente: Antiviral Res;120: 101-11, 2015 Aug.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 26022197
Resumen: The influenza A virus is notoriously known for its ability to cause recurrent epidemics and global pandemics. Antiviral therapy is effective when treatment is initiated within 48h of symptom onset, and delaying treatment beyond this time frame is associated with decreased efficacy. Research on anti-inflammatory therapy to ameliorate influenza-induced inflammation is currently underway and seems important to the impact on the clinical outcome. Both antiviral and anti-inflammatory drugs with (mas)

A Novel Antiviral Target Structure Involved in the RNA Binding, Dimerization, and Nuclear Export Functions of the Influenza A Virus Nucleoprotein.

Autor(es): Kakisaka M; Sasaki Y; Yamada K; Kondoh Y; Hikono H; Osada H; Tomii K; Saito T; Aida Y
Fuente: PLoS Pathog;11(7): e1005062, 2015 Jul.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 26222066
Resumen: Developing antiviral therapies for influenza A virus (IAV) infection is an ongoing process because of the rapid rate of antigenic mutation and the emergence of drug-resistant viruses. The ideal strategy is to develop drugs that target well-conserved, functionally restricted, and unique surface structures without affecting host cell function. We recently identified the antiviral compound, RK424, by screening a library of 50,000 compounds using cell-based infection assays. RK424 showed potent (mas)

Influenza A Virus Protein PA-X Contributes to Viral Growth and Suppression of the Host Antiviral and Immune Responses.

Autor(es): Hayashi T; MacDonald LA; Takimoto T
Fuente: J Virol;89(12): 6442-52, 2015 Jun.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25855745
Resumen: UNLABELLED: Influenza virus infection causes global inhibition of host protein synthesis in infected cells. This host shutoff is thought to allow viruses to escape from the host antiviral response, which restricts virus replication and spread. Although the mechanism of host shutoff is unclear, a novel viral protein expressed by ribosomal frameshifting, PA-X, was found to play a major role in influenza virus-induced host shutoff. However, little is known about the impact of PA-X expression o (mas)

Degree of adherence to recommended antiviral treatment during the pandemic and post-pandemic periods of influenza A(H1N1)pdm09 in 148 intensive care units in Spain.

Autor(es): Canadell L; Martín-Loeches I; Díaz E; Trefler S; Grau S; Yebenes JC; Almirall J; Olona M; Sureda F; Blanquer J; Rodriguez A
Fuente: Med Intensiva;39(4): 222-33, 2015 May.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25107582
Resumen: OBJECTIVE: To determine the degree of antiviral treatment recommendations adherence and its impact to critical ill patients affected by influenza A(H1N1)pdm09 mortality. DESIGN: Secondary analysis of prospective study. SETTING: Intensive care (UCI). PATIENTS: Patients with influenza A(H1N1)pdm09 in the 2009 pandemic and 2010-11 post-Pandemic periods. VARIABLES: Adherence to recommendations was classified as: Total (AT); partial in doses (PD); partial in time (PT), and non-adherence (NA). Vi (mas)

Mitochondrial antiviral signaling adaptor mediated apoptosis in H3N2 swine influenza virus infection is inhibited by viral protein NS1 in vitro.

Autor(es): Zhang J; Miao J; Hou J; Lu C
Fuente: Vet Immunol Immunopathol;165(1-2): 34-44, 2015 May 15.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25800220
Resumen: We investigated the in vitro role of mitochondrial antiviral signaling adaptor (MAVS) in apoptosis induced by H3N2 swine influenza virus infection and the influence of viral NS1 (nonstructural protein 1) protein on this process. H3N2 swine influenza virus (SIV, A/Swine/Shandong/3/2005) was co-cultured with human lung epithelial A549 cells. The relationship of MAVS expression to SIV replication and apoptosis, and the influence of viral proteins on MAVS functions were studied. The data indica (mas)

Assessing the use of antiviral treatment to control influenza.

Autor(es): Kramer SC; Bansal S
Fuente: Epidemiol Infect;143(8): 1621-31, 2015 Jun.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25274250
Resumen: Vaccines are the cornerstone of influenza control policy, but can suffer from several drawbacks. Seasonal influenza vaccines are prone to production problems and low efficacies, while pandemic vaccines are unlikely to be available in time to slow a rapidly spreading global outbreak. Antiviral therapy was found to be beneficial during the influenza A(H1N1)pdm09 pandemic even with limited use; however, antiviral use has decreased further since then. We sought to determine the role antiviral t (mas)

Estimating the United States demand for influenza antivirals and the effect on severe influenza disease during a potential pandemic.

Autor(es): O'Hagan JJ; Wong KK; Campbell AP; Patel A; Swerdlow DL; Fry AM; Koonin LM; Meltzer MI
Fuente: Clin Infect Dis;60 Suppl 1: S30-41, 2015 May 1.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25878299
Resumen: Following the detection of a novel influenza strain A(H7N9), we modeled the use of antiviral treatment in the United States to mitigate severe disease across a range of hypothetical pandemic scenarios. Our outcomes were total demand for antiviral (neuraminidase inhibitor) treatment and the number of hospitalizations and deaths averted. The model included estimates of attack rate, healthcare-seeking behavior, prescription rates, adherence, disease severity, and the potential effect of antivi (mas)

Antiviral Activity of the Human Cathelicidin, LL-37, and Derived Peptides on Seasonal and Pandemic Influenza A Viruses.

Autor(es): Tripathi S; Wang G; White M; Qi L; Taubenberger J; Hartshorn KL
Fuente: PLoS One;10(4): e0124706, 2015.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25909853
Resumen: Human LL-37, a cationic antimicrobial peptide, was recently shown to have antiviral activity against influenza A virus (IAV) strains in vitro and in vivo. In this study we compared the anti-influenza activity of LL-37 with that of several fragments derived from LL-37. We first tested the peptides against a seasonal H3N2 strain and the mouse adapted H1N1 strain, PR-8. The N-terminal fragment, LL-23, had slight neutralizing activity against these strains. In LL-23V9 serine 9 is substituted by (mas)

Inhalable dry powder formulations of siRNA and pH-responsive peptides with antiviral activity against H1N1 influenza virus.

Autor(es): Liang W; Chow MY; Lau PN; Zhou QT; Kwok PC; Leung GP; Mason AJ; Chan HK; Poon LL; Lam JK
Fuente: Mol Pharm;12(3): 910-21, 2015 Mar 2.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25599953
Resumen: Pulmonary delivery of siRNA has considerable therapeutic potential for treating viral respiratory infectious diseases including influenza. By introducing siRNA that targets the conserved region of viral genes encoding nucleocapsid protein (NP), viral mRNAs can be degraded and viral replication can be inhibited in mammalian cells. To enable siRNA to be used as an antiviral agent, the nucleic acid delivery barrier must be overcome. Effective local delivery of siRNA to lung tissues is required (mas)

A novel video tracking method to evaluate the effect of influenza infection and antiviral treatment on ferret activity.

Autor(es): Oh DY; Barr IG; Hurt AC
Fuente: PLoS One;10(3): e0118780, 2015.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25738900
Resumen: Ferrets are the preferred animal model to assess influenza virus infection, virulence and transmission as they display similar clinical symptoms and pathogenesis to those of humans. Measures of disease severity in the ferret include weight loss, temperature rise, sneezing, viral shedding and reduced activity. To date, the only available method for activity measurement has been the assignment of an arbitrary score by a 'blind' observer based on pre-defined responsiveness scale. This manual s (mas)

Oseltamivir-resistant influenza A(H1N1)pdm2009 strains found in Brazil are endowed with permissive mutations, which compensate the loss of fitness imposed by antiviral resistance.

Autor(es): Lopes e Souza TM; Fintelman-Rodrigues N; Resende PC; Mesquita M; Gregianini TS; Bozza FA; Pecego AC; Fernandes SB; Cury AL; Riediger IN; Siqueira MM
Fuente: Mem Inst Oswaldo Cruz;110(1): 101-5, 2015 Feb.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 25742269
Resumen: The 2009 pandemic influenza A virus outbreak led to the systematic use of the neuraminidase (NA) inhibitor oseltamivir (OST). Consequently, OST-resistant strains, carrying the mutation H275Y, emerged in the years after the pandemics, with a prevalence of 1-2%. Currently, OST-resistant strains have been found in community settings, in untreated individuals. To spread in community settings, H275Y mutants must contain additional mutations, collectively called permissive mutations. We display t (mas)
Resultados  1-12 de 282